WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Merck Group

MerckMerck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials - and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

www.merckgroup.com

Merck KGaA RSS Channel

Filters
List of articles in category Merck Group
Title Published Date
Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection 03 July 2020
Merck donates one billionth praziquantel tablet 30 January 2020
Merck pioneers new effort to see MS from the inside out 30 May 2019
Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China 19 March 2019
Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology 14 March 2019
Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline 06 February 2019
Merck Granted U.S. Patent for novel combination of Artificial Intelligence and Blockchain Technology 30 January 2019
Merck and Tencent announce collaboration on intelligent digital healthcare services in China 24 January 2019
Merck welcomes ten new startups to its Innovation Center 16 January 2019
Merck assigns Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon 20 December 2018
Syntropy to unlock the value of scientific data in fight to end cancer 20 November 2018
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer 19 November 2018
Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets) 10 October 2018
The Merck Accelerator Program 2019 20 September 2018
Merck awarded Australian CRISPR nickase patent for foundational genome-editing technology 15 August 2018
Merck launches online platform fertility.com 03 July 2018
Merck partners with Medisafe to help improve medication adherence for cardiometabolic patients 28 March 2018
Merck and three partners start ExploreBio, a € 20 million pre-seed investment initiative in Israel 20 February 2018
Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries 12 February 2018
Merck celebrates its 350th anniversary 05 February 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
  • End

Business & Industry

  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
  • Pfizer invests $43 billion to battle cancer

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Merck Group
  4. 100 healthy years - are kids prepared?

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.